Off-label use of infliximab Off-label-Anwendung von Infliximab

ÖNDER M., Salavastru C., Fritz K.

Hautarzt, cilt.64, sa.10, ss.757-761, 2013 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 64 Sayı: 10
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00105-013-2596-z
  • Dergi Adı: Hautarzt
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.757-761
  • Anahtar Kelimeler: Antagonist, Cytokine, Inflammation, Monoclonal antibody, Tumor necrosis factor α
  • Ankara Üniversitesi Adresli: Hayır

Özet

Tumor necrosis factor α (TNFα) is a pro-inflammatory cytokine and a key mediator of inflammation. Several TNFα antagonists have been used therapeutically. One of them, infliximab, is a chimeric monoclonal antibody with anti-TNFα activity. Numerous studies have shown TNFα antagonists to be effective in treating psoriasis-particularly severe resistant forms-and arthritis. Additionally, several case reports and studies showing the effects of TNFα on new dermatologic indications have been published. The intention of this review is to summarize the new off-label uses of infliximab according to published data. © 2013 Springer-Verlag Berlin Heidelberg.